Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes


Journal article


N. Temperton, P. Chan, G. Simmons, M. Zambon, R. Tedder, Y. Takeuchi, R. Weiss
Emerging infectious diseases, 2005

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Temperton, N., Chan, P., Simmons, G., Zambon, M., Tedder, R., Takeuchi, Y., & Weiss, R. (2005). Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes. Emerging Infectious Diseases.


Chicago/Turabian   Click to copy
Temperton, N., P. Chan, G. Simmons, M. Zambon, R. Tedder, Y. Takeuchi, and R. Weiss. “Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes.” Emerging infectious diseases (2005).


MLA   Click to copy
Temperton, N., et al. “Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes.” Emerging Infectious Diseases, 2005.


BibTeX   Click to copy

@article{n2005a,
  title = {Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes},
  year = {2005},
  journal = {Emerging infectious diseases},
  author = {Temperton, N. and Chan, P. and Simmons, G. and Zambon, M. and Tedder, R. and Takeuchi, Y. and Weiss, R.}
}

Abstract

SARS-CoV spike protein pseudotypes are the basis of an in vitro microneutralization assay sensitive and specific for SARS-CoV neutralizing antibodies.